Filing Flows › Voyager Therapeutics (VYGR) › Q3 2026
Voyager Therapeutics (VYGR) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Voyager Therapeutics (VYGR) reported revenue of $4.0M for the third quarter 2026 (Q3 2026), -70% from a year earlier and +27% from the quarter before. Operating margin was -658.2%, net loss $24.7M (615.2% of revenue).
Voyager Therapeutics, Q3 2026: revenue $4.0M (-70% year over year), operating margin -658.2%, net loss $24.7M, operating cash flow −$19.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.0M | +27% | -70% |
| Operating profit | −$26.4M | — | — |
| Net earnings | −$24.7M | — | — |
| Operating cash flow | −$19.7M | — | — |
What changed
Revenue was $4.0M in Q3 2026, down 70% year over year and up 27% from the previous quarter.
Operating costs exceeded revenue by $26.4M, an operating margin of -658.2%. Total costs fell 31% while revenue fell 70%. The quarter ended with a net loss of $24.7M, wider than the previous quarter's $24.5M loss.
Operating cash flow was −$19.7M. Non-cash charges added back $836K of depreciation and $2.6M of share-based compensation. Working capital and other items added $1.6M.
Questions
What was Voyager Therapeutics' revenue in the third quarter 2026?
Voyager Therapeutics (VYGR) reported revenue of $4.0M for the third quarter 2026 (Q3 2026), -70% from a year earlier and +27% from the quarter before.
Was Voyager Therapeutics profitable in the third quarter 2026?
Operating loss was $26.4M (-658.2% of revenue) and net loss $24.7M.